마이크로바이옴 시퀀싱 서비스 시장 : 샘플 유형별, 기술별, 용도별, 최종 사용자별 시장 예측(2026-2032년)

The Microbiome Sequencing Services Market is projected to grow by USD 619.13 million at a CAGR of 11.33% by 2032.

Microbiome sequencing services are becoming core infrastructure for precision health, pharmaceutical discovery, food safety, agriculture, environmental monitoring, and consumer wellness. Service providers combine sample preparation, 16S rRNA sequencing, shotgun metagenomics, metatranscriptomics, long-read sequencing, and bioinformatics to profile microbial communities with higher taxonomic and functional resolution.

Demand is supported by validated scientific programs such as the NIH Human Microbiome Project, expanding public repositories including NCBI Sequence Read Archive and MGnify, and broader adoption of next-generation sequencing in clinical and translational research. Buyers increasingly prioritize reproducible workflows, contamination control, metadata quality, secure data handling, and interpretable outputs that can support research decisions, product development, and regulatory documentation.

Transformative Shifts in the Microbiome Sequencing Landscape

The landscape is shifting from discovery-only microbiome profiling toward decision-grade microbial intelligence. Short-read platforms remain widely used for scalable 16S rRNA and shotgun metagenomic studies, while long-read sequencing improves genome assembly, strain tracking, plasmid and mobile genetic element analysis, and antimicrobial resistance gene context.

Service differentiation now depends on integrated wet-lab and bioinformatics quality. Customers expect standardized DNA extraction, spike-in and negative controls, host DNA depletion options, curated reference databases, and transparent pipelines using established tools such as QIIME 2, DADA2, Kraken, MetaPhlAn, HUMAnN, and assembly-based methods. The strongest providers also support multi-omics integration, longitudinal study design, sample-chain traceability, and compliant data governance.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is improving microbiome sequencing services by accelerating quality control, taxonomic classification, functional annotation, biomarker discovery, and cohort stratification. Machine learning models can detect batch effects, flag low-biomass contamination patterns, prioritize microbial signatures, and integrate microbiome profiles with metabolomics, clinical variables, diet, geography, and medication exposure.

The most credible AI adoption is explainable and validation-led. Because microbiome datasets are compositional, sparse, and highly affected by collection and extraction methods, industry leaders are applying cross-validation, external cohort testing, model interpretability, and reproducible feature engineering. AI is therefore most valuable when paired with rigorous metadata standards, transparent bioinformatics, and human scientific review rather than treated as a standalone insight engine.

Key Regional Insights

North America remains a leading region for microbiome sequencing services due to strong academic medical centers, biopharma R&D, clinical research networks, venture-backed therapeutics, and mature next-generation sequencing infrastructure. Europe benefits from large public research networks, biobanking capacity, national genomics initiatives, and strong data-protection requirements that favor validated, privacy-aware workflows. Asia-Pacific is expanding rapidly as China, Japan, South Korea, India, Singapore, and Australia invest in genomics, population-scale research, probiotics, infectious disease monitoring, and agricultural biotechnology.

Latin America is gaining traction through infectious disease research, biodiversity studies, food systems, and growing sequencing capacity in Brazil and Mexico. The Middle East is investing in precision medicine, national genomics, healthcare modernization, and high-quality laboratory infrastructure, particularly across GCC economies. Africa's opportunity is linked to infectious disease surveillance, soil and water microbiomes, antimicrobial resistance monitoring, agriculture resilience, and biodiversity research, although funding continuity, sample logistics, workforce development, and local sequencing infrastructure remain critical constraints.

Key Group Insights

ASEAN demand is supported by Singapore's biomedical ecosystem, Thailand and Malaysia's food and agriculture research, and regional interest in infectious disease, gut health, probiotics, aquaculture, and environmental microbiomes. GCC countries are emphasizing precision medicine, hospital modernization, national health programs, and population health initiatives that create demand for secure, clinically aligned microbiome sequencing workflows. The European Union's research funding, harmonized regulatory environment, cross-border scientific collaboration, and GDPR-driven data standards encourage robust consent, traceability, privacy protection, and reproducibility.

BRICS countries combine large populations, diverse diet and exposure profiles, public health needs, agricultural priorities, and expanding sequencing capacity, making them important centers for cost-efficient microbiome sequencing services. G7 markets continue to lead in pharmaceutical applications, companion diagnostics research, regulated clinical studies, and advanced multi-omics integration. NATO countries, while not a commercial bloc, collectively influence biosecurity, pathogen surveillance, antimicrobial resistance monitoring, and resilient laboratory networks relevant to microbiome sequencing providers.

Key Country Insights

The United States leads through NIH-funded microbiome research, biotech innovation, contract research networks, hospital-linked translational programs, and strong demand from pharma, nutrition, and clinical research. Canada contributes through population health, environmental microbiology, Indigenous and northern health research frameworks, and academic consortia, while Mexico and Brazil show rising demand in infectious disease, agriculture, food systems, and biodiversity studies. The United Kingdom, Germany, France, Italy, and Spain are supported by strong life-science clusters, biobanks, hospitals, public research funding, and European research collaboration, while Russia maintains expertise in genomics, microbial ecology, and environmental microbiology despite geopolitical and procurement constraints.

China has scaled sequencing capacity and supports microbiome applications across healthcare, agriculture, food safety, and consumer health. India is expanding through genomics initiatives, pharmaceutical services, public health research, and cost-competitive bioinformatics talent. Japan and South Korea emphasize advanced sequencing, probiotics, aging-related research, medical technology, and high-quality clinical research infrastructure. Australia combines strong clinical research, agricultural genomics, marine and environmental microbiome programs, and biosecurity priorities, positioning it as a high-quality service hub in the Asia-Pacific region.

Actionable Recommendations for Industry Leaders

Industry leaders should invest in validated end-to-end workflows that connect collection kits, extraction protocols, sequencing depth, positive and negative controls, contamination assessment, and bioinformatics outputs. Clear service menus for 16S rRNA sequencing, shotgun metagenomics, metatranscriptomics, viromics, mycobiomics, and long-read sequencing help customers match study goals with budget, resolution, sample type, and turnaround requirements.

Providers should also build defensible data assets by improving metadata capture, adopting FAIR data principles, documenting pipeline versions, and offering secure cloud-based delivery with role-based access. Strategic partnerships with hospitals, contract research organizations, probiotic and nutrition companies, agritech firms, food safety laboratories, and public health agencies can expand demand. Commercial success will depend on scientific transparency, regulatory readiness, AI governance, consultative study design, and evidence-based reporting that customers can reproduce and audit.

Research Methodology

This executive summary is developed from secondary research using peer-reviewed microbiome literature, public genomics resources, regulatory guidance, sequencing technology documentation, and recognized institutional programs. Key evidence sources include public repositories such as NCBI Sequence Read Archive, EMBL-EBI resources, MGnify, established analytical frameworks, and documented applications across clinical, pharmaceutical, food, agriculture, environmental, and public health research.

The analysis prioritizes verifiable market signals: sequencing platform adoption, bioinformatics standardization, regional research capacity, data governance requirements, public funding activity, and application-specific demand. Insights are synthesized to support strategic planning for microbiome sequencing service providers, investors, laboratories, and enterprise buyers while avoiding unsupported market-size claims, market-share references, or speculative performance figures.

Conclusion

Microbiome sequencing services are moving from exploratory profiling to high-value biological intelligence that supports therapeutic development, precision nutrition, infectious disease research, agriculture, environmental monitoring, food safety, and public health. Sector advancement is being shaped by improved sequencing chemistry, long-read adoption, scalable bioinformatics, AI-enabled interpretation, stronger metadata standards, and increasing expectations for reproducibility.

The most competitive providers will combine scientific rigor with operational scalability. Organizations that can deliver validated workflows, secure data environments, transparent analytics, contamination-aware reporting, and regionally relevant expertise will be best positioned to capture demand as microbiome research becomes more integrated with precision medicine, product development, antimicrobial resistance surveillance, and global bioeconomy strategies.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Microbiome Sequencing Services Market, by Sample Type

• 7.1. Fecal
• 7.2. Oral
• 7.3. Skin
• 7.4. Soil
• 7.5. Water

8. Microbiome Sequencing Services Market, by Technology

• 8.1. Amplicon Sequencing
  • 8.1.1. 16S Rrna Sequencing
  • 8.1.2. Internal Transcribed Spacer Sequencing
• 8.2. Metatranscriptomic Sequencing
• 8.3. Shotgun Metagenomic Sequencing

9. Microbiome Sequencing Services Market, by Application

• 9.1. Agricultural & Animal Husbandry
  • 9.1.1. Crop Quality Monitoring
  • 9.1.2. Livestock Health Monitoring
• 9.2. Clinical Diagnostics
  • 9.2.1. Gastrointestinal Disorder Diagnosis
  • 9.2.2. Infectious Disease Diagnostics
• 9.3. Consumer Genomics
  • 9.3.1. At-Home Testing
  • 9.3.2. Clinic-Based Testing
• 9.4. Environmental Monitoring
  • 9.4.1. Soil Health Monitoring
  • 9.4.2. Water Quality Monitoring
• 9.5. Pharmaceutical R&D
  • 9.5.1. Drug Discovery
  • 9.5.2. Microbiome Therapeutics Development

10. Microbiome Sequencing Services Market, by End User

• 10.1. Academic & Research Institutes
• 10.2. Clinical Diagnostic Laboratories
• 10.3. Consumer Genomics Companies
• 10.4. Contract Research Organizations
• 10.5. Pharmaceutical & Biopharmaceutical Companies

11. Microbiome Sequencing Services Market, by Region

• 11.1. Asia-Pacific
• 11.2. North America
• 11.3. Latin America
• 11.4. Europe
• 11.5. Middle East
• 11.6. Africa

12. Microbiome Sequencing Services Market, by Group

• 12.1. ASEAN
• 12.2. GCC
• 12.3. European Union
• 12.4. BRICS
• 12.5. G7
• 12.6. NATO

13. Microbiome Sequencing Services Market, by Country

• 13.1. United States
• 13.2. Canada
• 13.3. Mexico
• 13.4. Brazil
• 13.5. United Kingdom
• 13.6. Germany
• 13.7. France
• 13.8. Russia
• 13.9. Italy
• 13.10. Spain
• 13.11. China
• 13.12. India
• 13.13. Japan
• 13.14. Australia
• 13.15. South Korea

14. Competitive Landscape

• 14.1. Market Concentration Analysis, 2025
  • 14.1.1. Concentration Ratio (CR)
  • 14.1.2. Herfindahl Hirschman Index (HHI)
• 14.2. Recent Developments & Impact Analysis, 2025
• 14.3. Product Portfolio Analysis, 2025
• 14.4. Benchmarking Analysis, 2025

15. Company Profiles

• 15.1. Agilent Technologies, Inc.
• 15.2. BaseClear B.V.
• 15.3. BGI Genomics Co., Ltd.
• 15.4. Charles River Laboratories
• 15.5. Clinical Microbiomics A/S
• 15.6. CosmosID
• 15.7. Danaher Corporation
• 15.8. Eurofins Scientific SE
• 15.9. Genetic Analysis AS
• 15.10. Metabiomics Corp.
• 15.11. Microba Life Sciences
• 15.12. Microbiome Insights Inc.
• 15.13. MicroGenDX
• 15.14. Molecular Research LP
• 15.15. Molzym GmbH & Co. KG
• 15.16. Merieux NutriSciences Corporation
• 15.17. Norgen Biotek
• 15.18. Novogene Co., Ltd.
• 15.19. Nucleome Informatics Pvt. Ltd.
• 15.20. Oxford Nanopore Technologies PLC
• 15.21. Pacific Bioscience of California, Inc.
• 15.22. PathoQuest
• 15.23. ProgenaBiome
• 15.24. Psomagen
• 15.25. QIAGEN N.V.
• 15.26. Rancho Biosciences
• 15.27. Resphera Biosciences, LLC
• 15.28. Shanghai Realbio Technology Co., Ltd.
• 15.29. Thermo Fisher Scientific, Inc.
• 15.30. Zymo Research Corporation